Biological Assembly 1  

 3D View: Structure | Electron Density

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PQS (software)

Biological Assembly 2  

 3D View: Structure | Electron Density

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors and generated by PQS (software)

Macromolecule Content

• Total Structure Weight: 66.11 kDa 
• Atom Count: 4632 
• Residue Count: 535 
• Unique protein chains: 1

1OB3

Structure of P. falciparum PfPK5

• DOI: 10.2210/pdb1OB3/pdb

• Classification: TRANSFERASE
• Organism(s): Plasmodium falciparum
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2003-01-24 Released: 2004-01-23 
• Deposition Author(s): Holton, S., Merckx, A., Burgess, D., Doerig, C., Noble, M., Endicott, J.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 0.231 
• R-Value Work: 0.191 
• R-Value Observed: 0.193 

Literature

Structures of P. Falciparum Pfpk5 Test the Cdk Regulation Paradigm and Suggest Mechanisms of Small Molecule Inhibition

Holton, S., Merckx, A., Burgess, D., Doerig, C., Noble, M., Endicott, J.

(2003) Structure 11: 1329

• PubMed: 14604523 
• DOI: 10.1016/j.str.2003.09.020
• Structures With Same Primary Citation


• PubMed Abstract: 
  

Plasmodium falciparum cell cycle regulators are promising targets for antimalarial drug design. We have determined the structure of PfPK5, the first structure of a P. falciparum protein kinase and the first of a cyclin-dependent kinase (CDK) not derived from humans. The fold and the mechanism of inactivation of monomeric CDKs are highly conserved across evolution. ATP-competitive CDK inhibitors have been developed as potential leads for cancer therapeutics. These studies have identified regions of the CDK active site that can be exploited to achieve significant gains in inhibitor potency and selectivity. We have cocrystallized PfPK5 with three inhibitors that target such regions. The sequence differences between PfPK5 and human CDKs within these inhibitor binding sites suggest that selective inhibition is an attainable goal. Such compounds will be useful tools for P. falciparum cell cycle studies, and will provide lead compounds for antimalarial drug development.

---

Organizational Affiliation: 

Laboratory of Molecular Biophysics, Department of Biochemistry, South Parks Road, OX1 3QU, Oxford, United Kingdom.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
CELL DIVISION CONTROL PROTEIN 2 HOMOLOG	A, B	288	Plasmodium falciparum	Mutation(s): 0  EC: 2.7.1 (PDB Primary Data), 2.7.11.22 (UniProt), 2.7.11.23 (UniProt)
Find proteins for Q07785 (Plasmodium falciparum (isolate K1 / Thailand)) Explore Q07785  Go to UniProtKB:  Q07785

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.90 Å
• R-Value Free: 0.231 
• R-Value Work: 0.191 
• R-Value Observed: 0.193 
• Space Group: C 1 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 222.088	α = 90
b = 44.267	β = 103.42
c = 63.044	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
MOSFLM	data reduction
SCALA	data scaling
MOLREP	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2003-01-24 
• Released Date: 2004-01-23 
Deposition Author(s): Holton, S., Merckx, A., Burgess, D., Doerig, C., Noble, M., Endicott, J.

Revision History 

• Version 1.0: 2004-01-23
  Type: Initial release
  
• Version 1.1: 2011-05-08
  Changes: Version format compliance
• Version 1.2: 2011-07-13
  Changes: Version format compliance